Business Description
Laurus Labs Ltd
ISIN : INE947Q01028
Total Employee Number:
7,059Compare
Compare
Traded in other countries / regions
540222.India IPO Date
2016-12-19Description
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.05 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.48 | |||||
Debt-to-EBITDA | 1.21 | |||||
Interest Coverage | 9.58 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 13.29 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.7 | |||||
3-Year EBITDA Growth Rate | 5.4 | |||||
3-Year EPS without NRI Growth Rate | 4.2 | |||||
3-Year FCF Growth Rate | 429.5 | |||||
3-Year Book Growth Rate | 9.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.06 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.13 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.2 | |||||
9-Day RSI | 84.69 | |||||
14-Day RSI | 80.65 | |||||
3-1 Month Momentum % | 40.27 | |||||
6-1 Month Momentum % | 57.98 | |||||
12-1 Month Momentum % | 81.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.33 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.03 | |||||
Days Inventory | 272.36 | |||||
Days Sales Outstanding | 100.78 | |||||
Days Payable | 139.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.11 | |||||
Dividend Payout Ratio | 0.1 | |||||
3-Year Dividend Growth Rate | -7.2 | |||||
Forward Dividend Yield % | 0.13 | |||||
5-Year Yield-on-Cost % | 0.09 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.54 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.29 | |||||
Operating Margin % | 21.28 | |||||
Net Margin % | 15.04 | |||||
EBITDA Margin % | 28.72 | |||||
FCF Margin % | 7.61 | |||||
OCF Margin % | 22.33 | |||||
ROE % | 22.5 | |||||
ROA % | 11.21 | |||||
ROIC % | 14.1 | |||||
3-Year ROIIC % | 2.55 | |||||
ROC (Joel Greenblatt) % | 22 | |||||
ROCE % | 25.39 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 89.78 | |||||
Forward PE Ratio | 79.44 | |||||
PE Ratio without NRI | 89.78 | |||||
Shiller PE Ratio | 159.81 | |||||
Price-to-Owner-Earnings | 100.46 | |||||
PS Ratio | 13.5 | |||||
PB Ratio | 18.51 | |||||
Price-to-Tangible-Book | 19.42 | |||||
Price-to-Free-Cash-Flow | 177.33 | |||||
Price-to-Operating-Cash-Flow | 60.46 | |||||
EV-to-EBIT | 62.72 | |||||
EV-to-EBITDA | 48.08 | |||||
EV-to-Revenue | 13.81 | |||||
EV-to-FCF | 178.46 | |||||
Price-to-GF-Value | 2.2 | |||||
Price-to-Projected-FCF | 17.43 | |||||
Price-to-Median-PS-Value | 3.12 | |||||
Price-to-Graham-Number | 9.75 | |||||
Earnings Yield (Greenblatt) % | 1.59 | |||||
FCF Yield % | 0.57 | |||||
Forward Rate of Return (Yacktman) % | -1.64 |
Laurus Labs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Laurus Labs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-01-22 17:00 | In 172 days | ||
| Third quarter earnings results for 2027 | 2027-01-22 | In 171 days | ||
| Second quarter earnings conference call for 2027 | 2026-10-23 17:00 | In 81 days | ||
| Second quarter earnings results for 2027 | 2026-10-23 | In 80 days | ||
| First quarter earnings conference call for 2027 | 2026-07-24 17:00 | 1,568.30 (-0.58%) | ||
| First quarter earnings results for 2027 | 2026-07-24 | 1,568.30 (-0.58%) | ||
| General meeting for 2026 | 2026-07-02 15:00 | 1,493.60 (-1.93%) | ||
| Annual report for 2026 | 2026-06-08 | 1,447.00 (+0.34%) | ||
| INR 1.200000 Cash Dividend | 2026-05-08 | 1,206.45 (+1.16%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-04-30 17:00 | 1,105.70 (+1.12%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||

